Home
About
Pricing
Log In

What are you looking for?

Home
Pricing
Back
Compare AU

Compare VAP vs. CURE

Compare shares and ETFs on the ASX that you can trade on Pearler.

Vanguard Australian Property Securities Index ETF

ASX

Buy

Buy

Global X S&P Biotech ETF

ASX

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Vanguard Australian Property Securities Index ETF (VAP) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

VAP

CURE

Popularity

Low

Low

Pearlers invested

918

82

Median incremental investment

$1,000.00

$674.92

Median investment frequency

Monthly

Monthly

Median total investment

$2,582.10

$2,316.30

Average age group

> 35

> 35

Key Summary

VAP

CURE

Strategy

VAP seeks to track the performance of the S&P/ASX 300 A-REIT Index before considering any additional expenses.

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 46.59m in AUM and 158 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

Top 3 holdings

Goodman Group (27.19 %)

Scentre Group (11.28 %)

Stockland (7.79 %)

Moderna Inc (2.72 %)

Exelixis Inc (1.80 %)

Amgen Inc (1.79 %)

Top 3 industries

Real Estate (99.39 %)

Other (0.61 %)

Health Care (100.00 %)

Other (10.24 %)

Top 3 countries

Australia (100.00 %)

United States (96.74 %)

Switzerland (1.43 %)

United Kingdom of Great Britain and Northern Ireland (1.23 %)

Management fee

0.23 %

0.45 %

Key Summary

VAP

CURE

Issuer

Vanguard

Global X

Tracking index

S&P/ASX 300 A-REIT Index - AUD

S&P Biotechnology Select Industry

Asset class

ETF

ETF

Management fee

0.23 %

0.45 %

Price

$91.21

$78.08

Size

$2.921 billion

$50.133 million

10Y return

32.47 %

N/A

Annual distribution yield (5Y)

4.11 %

0.03 %

Market

ASX

ASX

First listed date

15/10/2010

12/11/2018

Purchase fee

$6.50

$6.50

Community Stats

VAP

CURE

Popularity

Low

Low

Pearlers invested

918

82

Median incremental investment

$1,000.00

$674.92

Median investment frequency

Monthly

Monthly

Median total investment

$2,582.10

$2,316.30

Average age group

> 35

> 35

Pros and Cons

VAP

CURE

Pros

  • Higher exposure to AU market

  • Lower management fee

  • Higher distribution yield

  • Higher exposure to US market

  • Higher price growth

Cons

  • Lower exposure to US market

  • Lower price growth

  • Lower exposure to AU market

  • Higher management fee

  • Lower distribution yield

VAP

CURE

Higher exposure to AU market

Lower exposure to AU market

Lower exposure to US market

Higher exposure to US market

Lower management fee

Higher management fee

Lower price growth

Higher price growth

Higher distribution yield

Lower distribution yield